Web Results

Vaso Active Pharmaceuticals, Inc., Debtors, Jeoffrey L. Burtch ...

www.deb.uscourts.gov/sites/default/files/opinions/judge-christopher-s.sontchi/opinion.8.11.14.pdf

Aug 11, 2014 ... FOR THE DISTRICT OF DELAWARE. In re: ) Chapter 11. ) VASO ACTIVE PHARMACEUTICALS, INC., ). ) Case No. 10-10855 (CSS). Debtors.

Cases | A.B. Data Class Action Administration

www.abdataclassaction.com/cases/

Beverly Enterprises - Arkansas, Inc., et al. and Vera Cooney and Eula Mae Allen, et al., v. Beverly ...... In re Vaso Active Pharmaceuticals Securities Litigation.

VASO ACTIVE PHARMACEUTICALS INC (VAPH) IPO - NASDAQ.com

www.nasdaq.com/markets/ipos/company/vaso-active-pharmaceuticals-inc-406348-34430

Company Name, VASO ACTIVE PHARMACEUTICALS INC. Company Address, 99 ROSEWOOD DRIVE, #260. DANVERS, MA 01923. Company Phone ...

A Vasoactive Role for Endogenous Relaxin in Mesenteric Arteries of ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4171481/

Sep 22, 2014 ... A vasoactive role for relaxin is supported by our recent data that .... ml TriReagent (Ambion Inc., Scoresbury, VIC, Australia) and total RNA was .... This could have been due to differences in compositional remodeling or re-arrangement of .... McGuane JT, Debrah JE, Sautina L, Jarajapu YPR, Novak J, et al.

Vasoactive intestinal peptide and pituitary adenylate cyclase ...

onlinelibrary.wiley.com/doi/10.1111/j.1432-1033.2004.04086.x/full

A radioligand-binding assay with <sup>125</sup>I-labeled vasoactive intestinal peptide (VIP) .... <sup>125</sup>I-Labelled VIP (81.4 TBq·mmol<sup>−1</sup>) was purchased from PerkinElmer Life Sciences Inc. ... CSE was prepared by a modification of the method of Carp et al. ..... VIP receptors in alveolar cells could be a pharmacological drug target for the  ...

Alarin is a vasoactive peptide

www.pnas.org/content/104/24/10217.full

Jun 12, 2007 ... The gene of the vasoactive intestinal peptide (VIP) is alternatively spliced .... binding assays were performed according to Berger et al. ... Full-length human galanin was purchased from Phoenix Pharmaceuticals (Belmont, .... Enigk RE ,; Maimone MM ..... Video content is hosted by Glencoe Software, Inc.

Depolarization Increases Vasoactive Intestinal Peptide - Journal of ...

www.jneurosci.org/content/12/10/3717.full.pdf

ganglion (SCG) of the adult rat (Hokfelt et al., 1977; Sasek and. Zigmond, 1989). ... synthesis, depolarization of sympathetic neurons has been re- ported to inhibit the .... by adding 1.5 PM veratridine (ICN Pharmaceuticals Inc., Plainview,. NY).

Full Text (PDF)

www.pnas.org/content/106/27/11282.full.pdf

Jul 7, 2009 ... heart failure while lacking the vasoactive properties of BNP. These findings ... Genome-wide analyses have revealed the prevalence of al- ternative .... Pan et al . PNAS. July 7 ... As alternative splicing usually affects coding re- .... BNP (hBNP, Phoenix Pharmaceuticals, Inc.) or ASBNP.1 (final concentration.

Vasoactive Factors and Inflammatory Mediators Produced in ...

link.springer.com/chapter/10.1007/978-1-59745-370-7_5

Abstract. In the search for mechanisms of obesity-mediated vascular pathology, attention has been focused on the role played by adipose tissue, ...

PDF(131K) - Wiley Online Library

onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.2005.tb00175.x/pdf

2IPS Pharma Inc., Sherbrooke, QC, CANADA; ... vasoactive mediators such as nitric oxide (NO) and prostaglandins. In chronic (30 ..... and ZDF fatty prehypertensive rats, CGS 35601, at 5 mg /kg/day re- ..... Bowen T, Cicardi M, Farkas H, et al.

More Info

Vaso Active Pharmaceuticals, Inc. : Lit. Rel. No. 18834 / August 17 ...

www.sec.gov

Aug 17, 2004 ... Litigation Release No. 18834 / August 17, 2004. SEC Files Settled Action Charging Vaso Active Pharmaceuticals, Inc. and its President and ...

Protected Graft Copolymer Excipient Leads to a Higher ... - PharmaIN

pharmain.com

icity of two nanoformulations of Vasoactive Intestinal Peptide (VIP). Methods VIP was .... mulations is primarily the function of drug:nanocarrier weight ratio or ... PGC was synthesized as described by Castillo et al. (4). Specifi- ... er 20 ml DCM and re-centrifuged. .... performed using GraphPad Prism (GraphPad Software Inc. ,.

A novel angiotensin-converting enzyme-related carboxypeptidase ...

www.ncbi.nlm.nih.gov

Sep 1, 2000 ... (1)Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA. ... of key vasoactive peptides suggest an essential role for ACE2 in the local ...